IonDX Inc., has focused on characterizing various classes of biotherapeutics (mAbs, protein complexes, ADCs, vaccines) and gene therapy (AAVs, CRISPR, mRNA) products. Our technology is used to investigate the higher order structure of proteins, nucleic acids and emerging classes of biological modalities. The majority of higher order structural analytics rely on indirect biophysical techniques because x-ray crystallography is not easily implemented in biotherapeutic workflows, and many other biologically manufactured products have never been crystallized. A well-recognized technical challenge is to screen and fingerprint macromolecular structures more rapidly. IonDX’s IMgenius™​ System utilizes atmospheric pressure ion mobility spectrometry (IMS) to screen complex structures.

Our patented spectrometer simultaneously measures five important attributes of biotherapeutics:
Size distribution
Structural heterogeneity
Stability
Comparability
Purity

The fast (5-10mins) analysis time and small footprint of our bench-top technology allow it to be utilized routinely throughout all stages of bioprocessing, including process monitoring. IonDX’s system, being amenable to automation, will fit into typical biotherapeutic high-throughput workflows, thus reducing time and effort to bring products to market.